Skip to main content
. 2014 Apr 14;1(5):340–347. doi: 10.1002/acn3.60

Figure 3.

Figure 3

Association between age and progression of percent brain atrophy at month 24. The Xs (riluzole) tend to be a bit shifted to the right compared to the circles (placebo) showing the older average age in the riluzole group. Although there are some older patients with more severe decline in the riluzole group, which could partially explain the differences, the largest declines in percent brain volume change (worse than 2%) were mostly in the treatment group (seven riluzole vs. one placebo subject) and were irrespective of age. In addition, a worsening in percent brain volume change worse than 1% at month 24 was seen almost equally in the placebo (n = 6) and the riluzole (n = 8) groups.